Product Pipeline
Our MELACINE ® melanoma vaccine is available for sale in Canada. MELACINE vaccine consists of lysed (broken) cells from two human melanoma cell lines combined with our proprietary DETOX™ adjuvant. DETOX adjuvant -- known outside of Canada as ENHANZYN™ adjuvant -- includes MPL® and mycobacterial cell wall skeleton, both of which activate the human immune system in the context of vaccination. We are currently in discussions with the FDA regarding the future regulatory path of MELACINE. The vaccine is administered as a two-shot vaccination once a week for five weeks, with a two-week break, and then a repeat of the weekly vaccinations for five weeks. Patients who respond may receive therapy of one vaccination per month for six months followed by less frequent maintenance vaccinations.

Related News
02/28/2002 ODAC endorses Phase III trial design for Melacine melanoma vaccine
01/15/2002 Corixa to present Melacine data and Phase III trial design to ODAC
02/15/2001 Melacine available in Canada
10/30/2000 Melacine phase III data presented at Society of Biological Therapy meeting
08/16/2000 Corixa holds first analyst summit
02/18/2000 Corixa presents Melacine phase III data
11/04/1999 Corixa receives Canadian Melacine approval
06/10/1999 Corixa to acquire Ribi
Publications
A panel immunoblot using co-incubated monoclonal antibodies for identification of melanoma cells
2001
Wang R, Dworak LJ, and Lacy MJ
Journal of Immunologic Methods
249/167-183
A panel immunoblot for identification of melanoma cells
2000
Dworak LJ, Wang R, and Lacy MJ
FASEB Journal
14/A1237
Duration of survival for disseminated malignant melanoma: Results of a meta-analysis
2000
Lee, ML, Tomsu, K, and Von Eschen, KB
Melanoma Res.
10(1)/81-92
A potential surrogate marker of efficacy for a therapeutic melanoma vaccine
1993
Elliott, GT, Perez, J, McLeod, RA, and Von Eschen, KB
Ann. NY Acad. Sci.
690/378-381
Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma
1993
Elliott, GT, McLeod, RA, Perez, J, and Von Eschen, KB
Semin. Surg. Oncol.
9/264-272
Results of a phase ii multicenter trial evaluating the activity of melacine melanoma theraccine in the treatment of disseminated melanoma (Meeting abstract)
1992
Elliott, GT, McLeod, RA, Perez, J, and Von Eschen, KB
Proceedings of the Annual Meeting American Assoc. of Cancer Res.
33/A1983
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Corixa's near-term products and adjuvant for research applications.